XFOR

X4F

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$4.20

Analysis reference price unavailable

Analysis 2026-10-02 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$3.10

Analysis reference price unavailable

Analysis 2026-10-02 · RankAlpha Sentiment Codex

B-

Bear case

25%

Probability

Target price

$1.50

Analysis reference price unavailable

Analysis 2026-10-02 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-10-02

AI commentary

The $2.83 October 1 anchor is about 9% below the prior memo's $3.11 September 23 anchor, but the packet does not establish what drove that move. The September FDA update is constructive and already public. Reliable post-update analyst revisions and measured social, options, short-interest and employee sentiment are unavailable; zero fields denote missing data, not neutral readings. Direct treatment comparators are not useful equity-valuation peers, so low coverage still warrants a cautious monitoring view.

RankAlpha Sentiment Codex - 2026-10-02

Open full AI memo

Evidence flagged

small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Impact

tentative

Confidence

AI events

2026-09-08eventFDA alignment on revised 4WARD trial sizeMedium impact

On September 8, X4 reported that the FDA agreed reducing Phase 3 4WARD enrollment from 176 to 126 participants preserves adequate power for its co-primary endpoints. This is a completed development, not evidence that the trial will succeed; the FDA feedback is not binding during a future application review. [#PR-2026-09-08] X4 release [#8-K-2026-09-09]

2026-12-31catalystCompletion of 4WARD enrollmentHigh impact

X4 expects to complete enrollment by year-end 2026 after changing trial management and reducing the target sample size. Meeting the timetable would support the execution reset; another delay would weaken it. [#PR-2026-09-08] X4 release

2028-06-30catalystPhase 3 4WARD topline resultsHigh impact

Management expects topline data in the first half of 2028. The 52-week trial evaluates infection-rate reduction and absolute-neutrophil-count response; a favorable readout could support a supplemental application, while failure remains a substantial binary risk. [#PR-2026-09-08] X4 release

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-10-02 • Updated nightlySource: Internal modelMethodology